Company
Official Name: Bristol-Myers Squibb Company
Headquarters: New York, NY, United States
Founded: 1887
Employees: 32,200
CEO: Dr. Giovanni Caforio M.D.
$130.84 Billion
USD as of July 1, 2023
Bristol Myers Squibb Company, also known as BMS, is a multinational pharmaceutical company. Tracing its origins to1858, it develops and manufactures prescription pharmaceuticals and biologics for a diverse range of diseases including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
Company | Market Cap (USD) |
---|---|
![]() |
$417.05 B |
![]() |
$412.24 B |
![]() |
$275.82 B |
![]() |
$241.08 B |
![]() |
$239.18 B |
Company | Market Cap (USD) |
---|---|
![]() |
$428.70 B |
![]() |
$417.05 B |
![]() |
$412.24 B |
![]() |
$329.83 B |
![]() |
$275.82 B |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Founder(s): William Mc Laren Bristol John Ripley Myers E. R. Squibb
Giovanni Caforio, M. D. (Chairman & CEO) David Elkins (CFO)
Revenue: US$42.518 billion (2020)
Operating income: US$30.745 billion (2020)
Net income: US$8.995 billion (2020)
Total assets: US$129.44 billion (2019)
Total equity: US$59.70 billion (2019)